支气管动脉灌注化疗加免疫治疗肺癌伴恶性胸水的价值研究  

Value Research of Bronchial Artery Infusion Chemotherapy Combined With Immunotherapy In Treatment of Lung Cancer With Malignant Pleural Effusion

作　　者：刘冬洁[1] 张旭阳 肖月 张义彬[1] 苑仁冰[1] 戚莎菲[1] LIU Dongjie;ZHANG Xuyang;XIAO Yue;ZHANG Yibin;YUAN Renbing;QI Safi(Oncology Department,Daqing Oilfield General Hospital,Daqing,Heilongjiang,163000)

机构地区：[1]大庆油田总医院肿瘤科,黑龙江大庆163000

出　　处：《智慧健康》2022年第3期67-69,共3页Smart Healthcare

摘　　要：目的探讨支气管动脉灌注化疗加免疫治疗肺癌伴恶性胸水的价值研究。方法将2018年1月-2020年12月在大庆油田总医院治疗的70例肺癌伴恶性胸水患者随机分为对照组和观察组,每组35例,对照组使用胸腔内化疗,在此基础上,观察组使用支气管动脉灌注化疗加免疫治疗,对比两组的近期疗效、免疫功能指标变化、不良反应。结果观察组治疗有效率为82.86%,明显高于对照组的65.71%(P<0.05);观察组治疗后CD^(3+)、CD^(4+)、CD^(4+)/CD^(8+)明显高于对照组,CD8+明显低于对照组(P<0.05);观察组发热、胸痛、恶心呕吐等不良反应发生率与对照组相比无明显差异(P>0.05)。结论支气管动脉灌注化疗加免疫治疗肺癌伴恶性胸水的价值显著,能提升对恶性胸水的抑制效果,调节机体免疫功能,不增加不良反应,具有积极的临床意义。Objective To investigate value of bronchial artery infusion chemotherapy and immunotherapy in treatment of lung cancer with malignant pleural effusion.Methods The paper chose 70 cases lung cancer patients with malignant pleural effusion treated in our hospital from January 2018 to December 2020,and divided them into control group and observation group randomly,with 35 cases in each group.Control group was treated with intrapleural chemotherapy.on the basis,observation group was treated with bronchial artery infusion chemotherapy and immunotherapy.Short-term effect,changes of immune function indexes and adverse reactions were compared between two groups.Results Effective rate in observation group was 82.86%,significantly higher than 65.71%in control group(P<0.05);after treatment,CD^(3+),CD^(4+),CD^(4+)/CD^(8+)in observation group were significantly higher than control group,and CD;was significantly lower than control group(P<0.05);there was no significant difference in adverse reactions incidence of fever,chest pain,nausea and vomiting between observation group and control group(P>0.05).Conclusion Bronchial artery infusion chemotherapy combined with immunotherapy can achieve significant value in treatment of lung cancer with malignant pleural effusion,improve inhibitory effect on malignant pleural effusion,regulate immune function,with no adverse reactions increase,which is of positive clinical significance.

关 键 词：肺癌伴恶性胸水 支气管动脉灌注化疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]